BERLIN (EGMN) - A phase III vaccine trial in renal cell carcinoma failed to meet its primary end point of improving overall survival, although an advantage was observed in a small subset of good-prognosis patients.Despite the disappointing results, investigator Dr. Robert Hawkins said that the Food and Drug Administration remains supportive of further development of the MVA-5T4 (TroVax) vaccine for possible use in metastatic colorectal, prostate, breast, and ovarian cancers.There was no evidence...